Skip to main content
Shalabh Gupta, MD, Physical Medicine/Rehab, New York, NY

Shalabh Kumar Gupta MD


Physician

Join to View Full Profile
  • 400 E 34th StNew York, NY 10016

  • Phone+1 212-263-6952

  • Fax+1 212-263-7146

Join Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Shalabh Gupta, MD is a physiatrist in New York, New York. He is currently licensed to practice medicine in New York and California.

Education & Training

  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Physical Medicine and Rehabilitation, 2001 - 2004
  • Jawaharlal Institute of Postgraduate Medical Education and Research
    Jawaharlal Institute of Postgraduate Medical Education and ResearchClass of 1996

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2008 - 2026
  • NY State Medical License
    NY State Medical License 2004 - 2012

Publications & Presentations

PubMed

Press Mentions

  • Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
    Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of HyperphosphatemiaMarch 13th, 2025
  • Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
    Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of RenazorbDecember 28th, 2022
  • Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
    Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United KingdomDecember 22nd, 2022
  • Join now to see all